Lasolvan tab 30mg 20 pc

$3.37

Lasolvan tab 30mg 20 pc

Quantity:

SKU: 1654355562 Categories: , , Tags: ,

Description

Composition
Active substance:
1 tablet contains: 30 mg of ambroxol hydrochloride ;.
Excipients:
171 mg lactose monohydrate, corn starch dried 36 mg, colloidal silicon dioxide 1.8 mg Magnesium stearate 1.2 mg.
Description:
Tablet – round, white or slightly yellow tablets, flat on both sides, with beveled edges on one side – the risk of dividing and engraving “67C” embossed on both sides of the break line on the other side of the tablet of the company symbol.
Product form:
Tablets 30 mg.
10 tablets in blisters (blister) made of PVC / Al foil on 2 or 5 blisters with instructions for use in a pile of cardboard.
Contraindications
Hypersensitivity to ambroxol or other components of the drug, pregnancy (I trimester), lactation, children under 18 years of age, the lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
Be wary of Mucosolvan in pregnancy (II – III trimester), renal and / or liver failure.
Dosage
30 mg
Indications
Acute and chronic respiratory disease with separation of viscous mucus: acute and chronic bronchitis, pneumonia, chronic obstructive pulmonary disease, bronchial asthma with difficulty sputum discharge, bronchiectasis.
Interaction with other drugs
Clinically significant, undesirable interactions with other drugs have not been reported. Increases penetration into the bronchial secretion of amoxicillin, cefuroxime, erythromycin.
Overdose
Specific symptoms of overdose in humans has not been described. There are reports of accidental overdose and / or medical error, which resulted in the observed symptoms known side effects of the drug Lasolvan: nausea, dyspepsia, vomiting, abdominal pain. In this case, the possible need for symptomatic therapy.
Treatment: artificial vomiting, gastric lavage in the first 1 to 2 hours after ingestion, symptomatic therapy.
pharmachologic effect
Pharmacological group:
Expectorant, mucolytic agent.
Pharmacodynamics:
The studies have shown that Ambroxol – the active ingredient Lasolvan – increases secretion in the airways. It enhances the production of pulmonary surfactant, and stimulates ciliary activity. These effects lead to increased transport current and mucus (mucociliary clearance). Strengthening improves mucociliary clearance of sputum expectoration and eases cough. In patients with chronic obstructive pulmonary disease Lazolvanom prolonged therapy (for at least 2 months) resulted in a significant reduction in the number obostreniyyu.
There was a significant decrease in the duration of exacerbations and the number of days of antibiotic therapy.
Pharmacokinetics:
For all dosage forms immediate release ambroxol is characterized by rapid and nearly complete absorption from the linear dependence on the dose of the therapeutic concentration range of maximum plasma concentration (Cmax) is reached after 1-2.5 hours after oral administration. Absolute bioavailability Mucosolvan tablets 30 mg is 79%. The volume of distribution is 552 liters. In the therapeutic concentration range of plasma protein binding is approximately 90%. Going ambroxol from blood to tissues after oral administration is rapid. The highest concentration of active ingredient of the drug are observed in the lungs. Approximately 30% of an oral dose is exposed to the effect of first pass through the liver.
Studies in human liver microsomes have shown that CYP3A4 isoenzyme is the predominant isoform responsible for the metabolism of ambroxol to dibromantranilovoy acid. The remainder of ambroxol is metabolized in the liver primarily by glucuronidation and by partial digestion to dibromantranilovoy acid (approximately 10% of the administered dose), and also a small amount of additional metabolites.
Period terminal floor you reference ambroxol is about 10 hours total clearance is in the range 660 ml / min for renal clearance accounting for about 83% of the total clearance
Not detected clinically significant effect of age and gender on the pharmacokinetics of ambroxol, there is no reason for the selection of dosage on these grounds.
Pregnancy and breast-feeding
Ambroxol crosses the placental barrier. Preclinical studies revealed no direct or indirect adverse effects on pregnancy, embryonic / fetal, postnatal development and labor. Extensive clinical experience with ambroxol after the 28th week of pregnancy found no evidence of a negative effect of the drug on the fetus.
However, you must observe the usual precautions when using the medication during pregnancy. Especially not recommended Lasolvan I trimester of pregnancy.
In II and III trimester of pregnancy, the use of the drug is possible only if the potential benefit to the mother outweighs the potential risk to the fetus.
Ambroxol is excreted in breast milk. Despite the fact that the undesirable effects in children receiving breast-feeding is not observed in the period of lactation is not recommended Lasolvan tablets.
Preclinical studies of ambroxol showed no negative effects on fertility.
Conditions of supply of pharmacies
Without recipe.
side effects
Disorders of the gastrointestinal tract
Often (1.0-10.0%) – nausea;
Infrequently (0.1-1.0%) – indigestion, vomiting, diarrhea, abdominal pain.
Immune system disorders, skin and subcutaneous tissue
Rarely (0.01-0.1%) – rash, urticaria; * angioneurotic edema, anaphylactic reactions (including anaphylactic shock), * * itch, hypersensitivity * data adverse reactions observed with the broad application of the drug; with 95% probability of data frequency of adverse reactions – rarely (0.1% -1.0%), but it is possible and below; the exact frequency is difficult to estimate, since they were not seen in clinical trials.
special instructions
It should not be combined with antitussive agents that prevent removal of sputum.
One tablet contains 162.5 mg of lactose. The maximum daily dose (4 tablets) contains 650 mg of lactose.
In patients with severe skin lesions – Stevens-Johnson syndrome or toxic epidermal necrolysis – in the early phase may appear fever, body pain, rhinitis, cough, and sore throat.
The symptomatic treatment of possible erroneous appointment of mucolytics such as ambroxol. There are few reports on the identification of Stevens-Johnson syndrome and toxic epidermal necrolysis, have coincided on the appointment of the drug; however, a causal relationship to drug intake is not.
With the development of the above syndromes is recommended to discontinue treatment and seek immediate medical attention.
If the kidney function Lasolvan should be used only under medical recommendation. For children under 18 may use other Mucosolvan formulations (syrup, lozenges for oral solution and inhalation).
Effect of the drug on the ability to drive mechanisms and
There were no cases of the influence of the drug on the ability to drive and use machines. Studies on the effect of the drug on the ability to drive and engage in other potentially hazardous activities that require high concentration and psychomotor speed reactions were not carried out.
Storage conditions
Store at a temperature not higher than 30 C.
Keep out of the reach of children.
Dosing and Administration
Inside.
30 mg (1 tablet) 3 times a day. If necessary for enhancing the therapeutic effect may be administered 60 mg (2 tablets), 2 times a day. The drug is taken with some liquid.
Taking tablets can be independent of food intake.
In the case of preservation of symptoms within 4-5 days from the start of the reception it is recommended to consult a doctor.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

SANOFI AVENTIS GROUP

There are no reviews yet.

Add your review